Sarepta Therapeutics, Inc.
$17.73+3.7%YTD-15.0%1Y-26.7%
Price updated 12m ago·X counts updated 8d ago
On X
The complete picture of $SRPT on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.
106X posts · last 7 days
Chatter Meter
1×
How loud $SRPT's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 68% of tracked names.
AI verdictAI analysisGenerated by AI from underlying data
TickerTalks' own read on what's driving $SRPT — fundamentals, momentum, or an event — and whether it agrees with the X crowd.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $SRPT.
Biotechnology
No material change from last week — mRNA oncology platform remains the structural driver.
What this means for $SRPT
Neutral — Commercial-stage biotech with approved exon-skipping drugs for Duchenne muscular dystrophy (EXONDYS 51, VYONDYS 53) and a gene therapy pipeline.
Top industry ETF
$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
30.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-1.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
-1.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
5.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
0.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
4.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
62.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$-0.05$0.22-123.0%
Q1 2026May 6, 2026$3.16$0.98+223.8%
Q4 2025Feb 25, 2026$-3.58$-1.03-247.6%
Q3 2025Nov 3, 2025$-1.80$-0.73-147.6%
Next earningsWed, Nov 4·consensus EPS $0.10
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$730.8M-1.9%83.7%49.0%$3.15$-205.8M
Q4 FY25$442.9M-32.7%10.0%-92.9%$-2.74$125.4M
Q3 FY25$399.4M-14.5%62.2%-25.9%$-1.80$-42.8M
Q2 FY25$611.1M+68.4%75.0%18.9%$2.01$229.4M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$1.8B$1.8B – $1.9B$3.14$2.30 – $4.2116
FY27$1.4B$1.2B – $1.6B$0.51$0.12 – $1.0315
FY28$1.3B$852.7M – $1.6B$0.22-$9.86 – $4.2313
FY29$1.3B$1.1B – $1.5B$0.85$0.67 – $1.0111
FY30$1.3B$1.1B – $1.5B$0.81$0.63 – $0.966
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.3.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.24%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-10.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-9.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatMid float · 100.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today9.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.205-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KMaterial agreementSep 238-K — Item 1.01: Material agreement
AI summary
3New insider — initial holdingsJul 293
AI summary
8-KOfficer or director changeJul 278-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary
8-KOfficer or director changeJun 48-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary
+ 17 other (6 13Gs · 2 13Fs · 2 earnings 8-Ks · 2 10-Qs) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual MeetingJim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner'Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPTSarepta Therapeutics (NASDAQ:SRPT) Given Sell Rating at HC WainwrightSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 3 · last 7 days